Home » Blogs » BioWorld Perspectives » Crowdfunding's slow march

BioWorld Perspectives
RSS

BioWorld

Crowdfunding's slow march

Jan. 29, 2015

By Michael Fitzhugh

No Comments

You must login or register in order to post a comment.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2023.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 11, 2023.
Off-target immune response from modified mRNA impacts future development
BioWorld
The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it...
‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s
BioWorld
For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...
Waging the losing battle: Altimmune takes on challengers as Pfizer falls back
BioWorld
Altimmune Inc.’s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe

BioWorld Perspectives RSS

Crowdfunding's slow march

Report Abusive Comment

BioWorld Perspectives
RSS